A drug used to treat trichomonas infections.
ChEBI ID: 50685
| Member | Definition | Class |
|---|---|---|
| benzoylmetronidazole | A benzoate ester resulting from the formal condensation of benzoic acid with the hydroxy group of metronidazole. | metronidazole benzoate |
| furazolidone | A member of the class of oxazolidines that is 1,3-oxazolidin-2-one in which the hydrogen attached to the nitrogen is replaced by an N-{[(5-nitro-2-furyl)methylene]amino} group. It has antibacterial and antiprotozoal properties, and is used in the treatment of giardiasis and cholera. | furazolidone |
| metronidazole | A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death. | metronidazole |
| ornidazole | A C-nitro compound that is 5-nitroimidazole in which the hydrogens at positions 1 and 2 are replaced by 3-chloro-2-hydroxypropyl and methyl groups, respectively. It is used in the treatment of susceptible protozoal infections and for the treatment of anaerobic bacterial infections. | ornidazole |
| Timeframe | Studies, Drugs with This Role(%) | All Drugs % |
|---|---|---|
| pre-1990 | 4,643 (32.75) | 18.7374 |
| 1990's | 2,503 (17.65) | 18.2507 |
| 2000's | 2,787 (19.66) | 29.6817 |
| 2010's | 3,149 (22.21) | 24.3611 |
| 2020's | 1,097 (7.74) | 2.80 |
| Publication Type | Studies, Drugs with this Role (%) | All Drugs (%) |
|---|---|---|
| Trials | 2,714 (17.23%) | 5.53% |
| Reviews | 1,357 (8.62%) | 6.00% |
| Case Studies | 2,307 (14.65%) | 4.05% |
| Observational | 54 (0.34%) | 0.25% |
| Other | 9,319 (59.16%) | 84.16% |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 7.9433 | 1 | 1 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 16.3601 | 1 | 1 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 21.6440 | 1 | 3 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 15.8489 | 1 | 1 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 56.2341 | 1 | 1 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 0.0898 | 1 | 1 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 0.1049 | 1 | 1 |
| geminin | Homo sapiens (human) | Potency | 9.9944 | 2 | 3 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 1.1883 | 1 | 1 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 130.6660 | 1 | 1 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 2.5119 | 1 | 1 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 12.3807 | 1 | 2 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 48.1208 | 1 | 3 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 70.6875 | 1 | 1 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 14.9601 | 1 | 1 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 7.9433 | 1 | 1 |
| TDP1 protein | Homo sapiens (human) | Potency | 9.4411 | 1 | 1 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 7.0795 | 1 | 1 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 15.8489 | 2 | 2 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 63.0957 | 1 | 1 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 2 |
| Bile salt export pump | Homo sapiens (human) | IC50 | 133.0000 | 1 | 2 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 2 |
| Lanosterol 14-alpha demethylase | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 2 |
| Thioredoxin reductase | Entamoeba histolytica | Ki | 3.3000 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | IC50 | 177.9000 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | IC50 | 177.9000 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | IC50 | 177.9000 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | IC50 | 177.9000 | 1 | 1 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| Flavodoxin | Helicobacter pylori 26695 | MIC | 67.3000 | 3 | 3 |